经皮冠状动脉(冠脉)介入治疗(PCI)临床应用30多年来,再狭窄一直是困扰其发展的重要原因,虽然冠动内支架的应用使之有所减少,但其发生率仍维持在10%~20%,在特殊人群甚至高达 50%。近年来以抗增生为目的的新型药物涂层支架(DES)的临床应用,取得了令人惊喜的效果。但是否通过 Clinical application of percutaneous coronary intervention (PCI) For more than 30 years, restenosis has been a major cause of its development. Although the application of intra-coronary stenting has been reduced, its incidence remains at 10% ~ 20%, even up to 50% in special populations. In recent years, anti-proliferation for the purpose of the new drug-coated stent (DES) clinical application, has achieved surprising results. But did you pass?